Patents by Inventor Daryl Lynn Smith
Daryl Lynn Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11773067Abstract: The present invention provides a compound of Formula I: wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.Type: GrantFiled: July 25, 2022Date of Patent: October 3, 2023Assignee: Eli Lilly and CompanyInventors: Daryl Lynn Smith, Leonard Larry Winneroski, Jr.
-
Publication number: 20220372003Abstract: The present invention provides a compound of Formula I: wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.Type: ApplicationFiled: July 25, 2022Publication date: November 24, 2022Inventors: Daryl Lynn Smith, Leonard Larry Winneroski, JR.
-
Patent number: 11414389Abstract: The present invention provides a compound of Formula I: wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.Type: GrantFiled: April 30, 2021Date of Patent: August 16, 2022Assignee: Eli Lilly and CompanyInventors: Daryl Lynn Smith, Leonard Larry Winneroski, Jr.
-
Publication number: 20210347738Abstract: The present invention provides a compound of Formula I: wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.Type: ApplicationFiled: April 30, 2021Publication date: November 11, 2021Inventors: Daryl Lynn Smith, Leonard Larry Winneroski, JR.
-
Patent number: 10227310Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.Type: GrantFiled: April 13, 2016Date of Patent: March 12, 2019Assignee: Eli Lilly and CompanyInventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
-
Publication number: 20180079729Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.Type: ApplicationFiled: April 13, 2016Publication date: March 22, 2018Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
-
Patent number: 7655641Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.Type: GrantFiled: February 10, 2004Date of Patent: February 2, 2010Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
-
Patent number: 7595339Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.Type: GrantFiled: August 17, 2007Date of Patent: September 29, 2009Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
-
Publication number: 20080287504Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.Type: ApplicationFiled: August 17, 2007Publication date: November 20, 2008Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, JR., Daryl Lynn Smith
-
Publication number: 20080167310Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.Type: ApplicationFiled: October 3, 2007Publication date: July 10, 2008Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky, Maria Rosario Gonzalez-Garcia
-
Patent number: 7282501Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.Type: GrantFiled: May 24, 2002Date of Patent: October 16, 2007Assignee: Eli Lilly and CompanyInventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky
-
Patent number: 7276516Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine.Type: GrantFiled: December 13, 2004Date of Patent: October 2, 2007Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Steven Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
-
Publication number: 20040198833Abstract: The present invention provides compounds of formula (I), useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: January 30, 2003Publication date: October 7, 2004Inventors: David Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Dennis Michael Zimmermann
-
Publication number: 20030225127Abstract: The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: April 1, 2003Publication date: December 4, 2003Inventors: David Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Publication number: 20030220369Abstract: The present invention provides certain heterocyclic sulfonamide derivatives of formula I: useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: ApplicationFiled: January 13, 2003Publication date: November 27, 2003Inventors: Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis MIchael Zimmerman